EA200800355A1 - Нейтрализующие антитела человека против b7rp1 - Google Patents

Нейтрализующие антитела человека против b7rp1

Info

Publication number
EA200800355A1
EA200800355A1 EA200800355A EA200800355A EA200800355A1 EA 200800355 A1 EA200800355 A1 EA 200800355A1 EA 200800355 A EA200800355 A EA 200800355A EA 200800355 A EA200800355 A EA 200800355A EA 200800355 A1 EA200800355 A1 EA 200800355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
b7rp1
antibodies
antibodies against
human antibodies
neutralizing human
Prior art date
Application number
EA200800355A
Other languages
English (en)
Other versions
EA021669B1 (ru
Inventor
Джералд Сиу
Веньянь Шень
Стивен Кийоши Йошинага
Хайчунь Хуань
Original Assignee
Амджен Инк.
Медарекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US70026505P priority Critical
Application filed by Амджен Инк., Медарекс, Инк. filed Critical Амджен Инк.
Priority to PCT/US2006/027862 priority patent/WO2007011941A2/en
Publication of EA200800355A1 publication Critical patent/EA200800355A1/ru
Publication of EA021669B1 publication Critical patent/EA021669B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В данном изобретении предложены антитела, которые взаимодействуют с человеческим В7-связанным белком-1 (B7RP1) или связываются с ним, и антитела, которые связываются с B7RP1 и посредством этого нейтрализуют его функцию. В изобретении также предложены фармацевтические композиции указанных антител и способы нейтрализации функции B7RP1 и, в частности, для лечения иммунных расстройств (например, неадекватного иммунного ответа) путем введения фармацевтически эффективного количества антител анти-В7RP1. Также предложены способы определения количества B7RP1 в образце с использованием антител против B7RP1.
EA200800355A 2005-07-18 2006-07-18 Нейтрализующие антитела человека против b7rp1 EA021669B1 (ru)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US70026505P true 2005-07-18 2005-07-18
PCT/US2006/027862 WO2007011941A2 (en) 2005-07-18 2006-07-18 Human anti-b7rp1 neutralizing antibodies

Publications (2)

Publication Number Publication Date
EA200800355A1 true EA200800355A1 (ru) 2008-08-29
EA021669B1 EA021669B1 (ru) 2015-08-31

Family

ID=37562100

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800355A EA021669B1 (ru) 2005-07-18 2006-07-18 Нейтрализующие антитела человека против b7rp1

Country Status (26)

Country Link
US (4) US7868140B2 (ru)
EP (7) EP1915398B1 (ru)
JP (1) JP5142998B2 (ru)
KR (4) KR101024758B1 (ru)
CN (1) CN101321783B (ru)
AU (1) AU2006270009A1 (ru)
BR (1) BRPI0614040A2 (ru)
CA (2) CA2854576A1 (ru)
CR (1) CR9745A (ru)
DK (1) DK1915398T3 (ru)
EA (1) EA021669B1 (ru)
ES (1) ES2572177T3 (ru)
HK (1) HK1120049A1 (ru)
HR (1) HRP20160875T1 (ru)
HU (1) HUE028830T2 (ru)
IL (6) IL188642A (ru)
MX (1) MX2008000734A (ru)
NO (1) NO20080302L (ru)
NZ (2) NZ604090A (ru)
PL (1) PL1915398T3 (ru)
RS (1) RS54984B1 (ru)
SG (2) SG196835A1 (ru)
SI (1) SI1915398T1 (ru)
UA (1) UA102667C2 (ru)
WO (1) WO2007011941A2 (ru)
ZA (1) ZA200801137B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
PT2332976E (pt) * 1999-02-03 2014-05-23 Amgen Inc Novos polipéptidos envolvidos na resposta imunitária
SG196835A1 (en) * 2005-07-18 2014-02-13 Amgen Inc Human anti-b7rp1 neutralizing antibodies
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2008293425B2 (en) * 2007-08-31 2014-09-18 Amgen Inc. Solid-state protein formulation
CA2701032A1 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
BR112012031121A2 (pt) 2010-06-07 2016-11-01 Amgen Inc dispositivo de distribuição de droga
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
CA2812389A1 (en) 2010-09-27 2012-04-12 John Kehoe Antibodies binding human collagen ii
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
JP6038884B2 (ja) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド 自動式注射装置
EP3335747A1 (en) 2011-10-14 2018-06-20 Amgen Inc. Injector and method of assembly
EP2922590A1 (en) 2012-11-21 2015-09-30 Amgen Inc. Drug delivery device
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
SG11201507208VA (en) * 2013-03-13 2015-10-29 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
US20150374919A1 (en) 2013-03-22 2015-12-31 Amgen Inc. Injector and method of assembly
US10472410B2 (en) 2013-04-23 2019-11-12 The University Court Of The University Of Aberdeen Isolation of therapeutic target specific VNAR domains to ICOSL
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP2016538096A (ja) 2013-10-24 2016-12-08 アムジエン・インコーポレーテツド 温度感知制御を伴う薬剤送達システム
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
RU2693084C2 (ru) * 2014-01-10 2019-07-01 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CN106536562A (zh) 2014-05-01 2017-03-22 泰华制药澳大利亚公司 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合,和其用途
CN106413779A (zh) 2014-05-07 2017-02-15 安姆根有限公司 具有减震元件的自助注射器
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2015187797A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Controllable drug delivery system and method of use
JP2017530817A (ja) 2014-10-14 2017-10-19 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
JP2017538512A (ja) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
US20180036476A1 (en) 2015-02-17 2018-02-08 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US20180305436A1 (en) * 2015-05-27 2018-10-25 Universita Degli Studi Del Piemonte Orientale "Amedeo Avogadro" Ligands of b7h receptor in the treatment of osteopenia and osteoporosis
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
KR20180072821A (ko) * 2015-11-03 2018-06-29 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
US20180318526A1 (en) 2015-12-09 2018-11-08 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
EP3429663A1 (en) 2016-03-15 2019-01-23 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US20190192766A1 (en) 2016-04-29 2019-06-27 Amgen Inc. Drug Delivery Device with Messaging Label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988A1 (en) 2016-05-16 2019-03-27 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
AU2018220538A1 (en) 2017-02-17 2019-06-27 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018231107A1 (en) 2017-03-06 2019-08-01 Amgen Inc. Drug delivery device with activation prevention feature
AU2018230546A1 (en) 2017-03-07 2019-08-22 Amgen Inc. Needle insertion by overpressure
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
SG11201907676PA (en) 2017-03-28 2019-09-27 Amgen Inc Plunger rod and syringe assembly system and method
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
US20190060562A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
WO2019191150A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
WO2019199476A1 (en) 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (de) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) * 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627D1 (de) 1990-08-29 1997-10-16 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
AU2249592A (en) 1991-06-14 1993-01-12 Dnx Corporation Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5625825A (en) * 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
PT2332976E (pt) * 1999-02-03 2014-05-23 Amgen Inc Novos polipéptidos envolvidos na resposta imunitária
KR20130105766A (ko) 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 사람 il-12에 결합하는 사람 항체 및 이의 제조방법
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
KR100942863B1 (ko) * 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
JP4737905B2 (ja) * 1999-09-21 2011-08-03 ジェネティクス インスティテュート,エルエルシー Gl50分子およびその使用
GB0016633D0 (en) 2000-07-07 2000-08-23 Bp Exploration Operating Process
EP2042596B1 (en) * 2000-11-28 2015-02-11 Amgen Inc. Polypeptides involved in immune response
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
JPWO2006003999A1 (ja) 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント
SG196835A1 (en) * 2005-07-18 2014-02-13 Amgen Inc Human anti-b7rp1 neutralizing antibodies
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
IL218889D0 (en) 2012-05-31
WO2007011941A3 (en) 2007-05-03
US10072090B2 (en) 2018-09-11
SG164369A1 (en) 2010-09-29
WO2007011941A2 (en) 2007-01-25
EP2397499A3 (en) 2013-12-25
PL1915398T3 (pl) 2016-10-31
SI1915398T1 (sl) 2016-07-29
KR20140097582A (ko) 2014-08-06
US7868140B2 (en) 2011-01-11
HUE028830T2 (en) 2017-01-30
US20080166352A1 (en) 2008-07-10
EP2388277A3 (en) 2013-03-20
MX2008000734A (es) 2008-03-19
EP2388276A3 (en) 2013-11-27
CA2854576A1 (en) 2007-01-25
US20160145345A1 (en) 2016-05-26
JP5142998B2 (ja) 2013-02-13
IL188642D0 (en) 2008-04-13
ES2572177T3 (es) 2016-05-30
NO20080302L (no) 2008-04-15
IL218890D0 (en) 2012-05-31
KR101024758B1 (ko) 2011-03-24
CA2614972C (en) 2014-08-19
KR20100101016A (ko) 2010-09-15
CN101321783B (zh) 2015-08-26
KR101263079B1 (ko) 2013-05-09
NZ625807A (en) 2015-11-27
EP2397496A3 (en) 2013-05-29
RS54984B1 (sr) 2016-11-30
US20130171695A1 (en) 2013-07-04
EA021669B1 (ru) 2015-08-31
EP2397499A2 (en) 2011-12-21
JP2009501549A (ja) 2009-01-22
IL218893D0 (en) 2012-05-31
US20110104757A1 (en) 2011-05-05
EP1915398A2 (en) 2008-04-30
CA2614972A1 (en) 2007-01-25
EP2397497A3 (en) 2013-11-27
DK1915398T3 (en) 2016-07-04
IL188642A (en) 2015-01-29
WO2007011941A9 (en) 2008-02-21
IL218888D0 (en) 2012-05-31
ZA200801137B (en) 2010-05-26
EP2397498A2 (en) 2011-12-21
US9266945B2 (en) 2016-02-23
KR20080049014A (ko) 2008-06-03
AU2006270009A1 (en) 2007-01-25
EP2397496A2 (en) 2011-12-21
UA102667C2 (ru) 2013-08-12
HRP20160875T1 (hr) 2016-09-23
CN101321783A (zh) 2008-12-10
US8981071B2 (en) 2015-03-17
HK1120049A1 (zh) 2017-07-14
CR9745A (es) 2008-07-22
BRPI0614040A2 (pt) 2011-03-09
IL218892D0 (en) 2012-05-31
EP1915398B1 (en) 2016-04-20
NZ604090A (en) 2014-07-25
SG196835A1 (en) 2014-02-13
EP2388277A2 (en) 2011-11-23
EP2397498A3 (en) 2013-11-27
EP2397497A2 (en) 2011-12-21
KR20130023356A (ko) 2013-03-07
EP2388276A2 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
RU2458071C2 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
RU2427590C2 (ru) Анти-mn антитела и способы их применения
DK3312197T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
EA200601313A1 (ru) Варианты участка f
BRPI0917470A2 (pt) anticorpos humanos que se ligam ao gene de ativação linfocitária-3(lag) e usos dos mesmos
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
EA200701131A1 (ru) Гелеобразная препаративная форма капсаициноида и способы её применения
BR112015007672A2 (pt) anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
CL2008001334A1 (es) Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
CL2016002816A1 (es) Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
CY1120191T1 (el) Συνθεση που περιλαμβανει αντισωμα που δεσμευεται με περιοχη ii toy her2 και οξινεσ παραλλαγεσ αυτου
MX2009006891A (es) Anticuerpos cd44.
UA94899C2 (ru) Фиксированное дозирование антител к her
BR112014005799A2 (pt) anticorpos para pcsk9, seus usos, e composição farmacêutica
ECSP10010644A (es) Inmunoglobulinas duales de dominio variable y sus aplicaciones
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EA200970556A1 (ru) Моноклональные антитела против angptl3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title